THE EFFECT OF LUNASIN ON LIVER HISTOPATHOLOGY OF MICE INDUCED BY AZOXIMETHANE (AOM) AND DEXTRAN SODIUM SULPHATE (DSS) by KUSMARDI et al.
 
 
    ISSN - 0975-7058 
Vol 11, Special Issue 6, 2019 
THE EFFECT OF LUNASIN ON LIVER HISTOPATHOLOGY OF MICE INDUCED BY 
AZOXIMETHANE (AOM) AND DEXTRAN SODIUM SULPHATE (DSS) 
Original Article 
 
KUSMARDI1, HERIYANTO KHIPUTRA2, SALINAH1* 
1Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, 2
Received: 12 Dec 2018, Revised and Accepted: 10 Mar 2019 
Faculty of Medicine, Universitas Indonesia 
Email: salinahsyarif@gmail.com 
ABSTRACT 
Objective: Azoximethane (AOM) and dextran sodium sulfate (DSS) are commonly used to induce colorectal cancer, but have side effects on the liver. 
AOM can induce hepatic histopathological changes such as the appearance of microvesicular steatosis and necrosis. DSS plays a role in causing 
inflammation and indirect scarring through colitis. This study aimed to determine in mice the effect of lunasin on the liver histopathology induced 
by AOM and DSS. 
Methods: This was an experimental study conducted in BALB/c mice. The data analyzed were the results of quantification of foci of necrosis, 
steatosis, and dysplasia from liver preparations of mice given lunasin extract at doses of 20, 30, and 40 mg/kg and control group. 
Results: This study showed a significant decrease in the number of foci of necrosis in the group given 30 mg/kg lunasin, with a mean score of 
9.0±3.4 compared with the control group mean score of 14.0±0.8 (P = 0.017). There was also a significant decrease in the number of foci of steatosis 
in the group given 30 mg/kg lunasin with a mean score of 3.8±1.3 compared with the control group mean score of 11.5±1.9 (P = 0.002).  
Conclusion: The results of this study indicate that lunasin at doses above 30 mg/kg can inhibit the formation of foci of necrosis and steatosis 
induced in mouse liver by AOM and DSS. 
Keywords: Azoxymethane, Dextran sodium sulfate, Liver, Mice, Lunasin 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ijap.2019.v11s6.33552 
 
INTRODUCTION 
Colorectal cancer is the third most commonly diagnosed cancer in 
men and the second most common in women. It accounts for over 
9% of all cancer incidence, with an estimated 1.4 million cases 
occurring in 2012 [1, 2]. 
Azoximethane (AOM) and dextran sodium sulfate (DSS) are 
commonly used to induce colorectal cancer in experimental models, 
but these substances have side effects on the liver. In studies using 
mice, it was found that AOM can induce hepatic histopathological 
changes such as the appearance of microvesicular steatosis, necrosis, 
and the growth of tumor nodules [3, 4]. DSS plays a role in causing 
inflammation and indirect scarring through colitis [5]. 
Lunasin is a chemical contained in soybeans that is considered to 
have anticancer effects. Lunasin has been demonstrated to prevent 
several types of cancer, including breast cancer, colon cancer, 
leukemia, and prostate cancer [6]. In addition to cancer, other 
diseases that cause damage through inflammation can be 
suppressed by lunasin because it affects the inflammatory and 
oxidative pathways that are risk factors for liver damage [6]. 
Lunasin has the ability to reduce proinflammatory gene expression 
through modulation of nuclear factor (NF)-κB [7]. 
There are few studies examining the effect of lunasin on changes in 
liver histopathology in experimental animals. Although soybean 
production in Indonesia is still relatively low compared with that in 
other soybean-producing countries, Indonesia pays special attention 
to soybeans as a food crop [8]. This study aimed to analyze the 
efficacy of lunasin in modulating liver histopathology changes 
induced by AOM and DSS. 
MATERIALS AND METHODS 
This study was previously approved by The Ethic Committee of the 
Faculty of Medicine, Universitas Indonesia, ethical number 181/UN2. 
F1/ETIK/2016. This study was performed using 20 male BALB/c 
mice, 12 w old and weighing±20 grams. Mice were acclimatized for 1 
w before being given AOM dissolved in 0.9% NaCl at a dose of 10 mg 
per kilogram of body weight intraperitoneally. Mice were given 
standard feed for 1 w then mineral water containing 2% DSS every 
day for 1 w. After that, mice in the test groups were given lunasin at 
varying doses every day for 6 w. The mice were then sacrificed, and 
the right lobe of the liver was embedded in paraffin. Slices of liver 
tissue 4 µm thick were stained with hematoxylin and eosin. 
The mice were divided into four groups: a control group that was 
not given lunasin, a group given 20 mg/kg body weight lunasin (low 
dose), a group given 30 mg/kg body weight lunasin (moderate 
dose), and a group given 40 mg/kg body weight lunasin (high dose). 
The independent variable in this study was the dose of lunasin given 
to the mice. The dependent variable was the number of foci of 
necrosis, steatosis, and dysplasia.  
This experimental study analyzed data from quantification of the 
number of foci of necrosis, steatosis, and dysplasia in mouse liver 
observed by light microscopy at 400× magnification. Quantification 
was performed by assessing 10 fields of view and summing the 
results. The data obtained in this study were processed using SPSS 
for Windows (SPSS) v. 20, the Shapiro–Wilk test for the normality of 
data distribution, and the Levene test for the homogeneity of 
variance. If the data distribution was normal and homogeneous, then 
the data were analyzed by a one-way analysis of variance (ANOVA) 
and Tukey’s honest significant difference (HSD) test. If the data 
distribution was not normal or homogeneous, then the data were 
analyzed with the Kruskal–Wallis test and the Games–Howell test. 
RESULTS 
During the study, one mouse from the control group died. The number of 
foci of necrosis and the mean for each group are listed in table 1. The 
results of the Shapiro–Wilk test and the Levene test showed normal data 
distributions and homogeneous variances. One-way ANOVA produced P 
= 0.005. The results of Tukey’s HSD test showed that there were 
significant differences between the control group and the moderate-and 
high-dose groups, with a mean score of 14.00±0.82 for the control group 
compared with a mean score of 9.00±3.39 for the moderate-dose group 
(P = 0.017) and of 8.20±1.64 for the high-dose group (P = 0.009). There 
was no significant difference between the control group and the low-
dose group, which had a mean score of 11.60±1.67 (P = 0.379). 
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Table 1: Number of foci of necrosis 
Sample Control 20 mg/kg lunasin 30 mg/kg lunasin 40 mg/kg lunasin 
1 15 9 4 6 
2 14 13 9 10 
3 14 11 13 9 
4 13 13 8 9 
5 0? 12 11 7 
Mean 14 11.6 9 8.2 
 
 
Fig. 1: The effect of various doses of lunasin on the number of hepatic foci of necrosis 
 
 
Fig. 2: Histopathological features of foci of liver necrosis. Hematoxylin and eosin staining, 400x (A). Control, (B). 20 mg/kg lunasin, (C). 30 
mg/kg lunasin, (D). 40 mg/kg lunasin 
 
The mean number of foci of steatosis in each group is shown in table 
2. The results of the Shapiro–Wilk test demonstrated normal data 
distributions, but the results of the Levene test showed that the 
intergroup variance was not homogeneous. The results of the 
Kruskal–Wallis test on the foci of steatosis obtained P = 0.002. The 
Games–Howell test showed a significant difference between the 
control, moderate and high doselunasin-treated groups, with a mean 
of 11.50±1.92 for the control group, 3.80±1.30 for the moderate-
dose group (P = 0.004), and 5.20±2.05 for the high-dose group (P = 
0.009). There was no significant difference between the control 
group and the low-dose lunasin group, which had a mean of 
8.00±0.71 (P = 0.091). 
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Table 2: Number of foci of steatosis 
Control 20 mg/kg lunasin 30 mg/kg lunasin 40 mg/kg lunasin 
1 14 8 6 3 
2 10 7 4 6 
3 12 8 3 7 
4 10 9 3 7 
5 - 8 3 3 
Mean 11.5 8 3.8 5.2 
 
 
Fig. 3: The effect of various doses of lunasin on the number of hepatic foci of steatosis 
 
 
Fig. 4: Histopathological features of the foci of liver steatosis. Hematoxylin and eosin staining, 400x (A). Control, (B). 20 mg/kg lunasin, 
(C). 30 mg/kg lunasin, (D). 40 mg/kg lunasin, No dysplasia induced by AOM and DSS was observed in any mouse liver preparation. 
 
DISCUSSION 
Observations showed that the number of foci of necrosis was reduced 
with increasing doses of lunasin. From the results of the analysis, it can 
be seen that there is a significant difference between the control group 
and the groups given lunasin at doses of 30 and 40 mg/kg, although 
there was no significant difference between the control group and the 
low-dose group. The effect of lunasin on the development of foci of 
necrosis has not been reported previously, but it has been reported 
that lunasin can inhibit the production of tumor necrosis factor α and 
interleukin-6 in RAW264 cells [8] stimulated by lipopolysaccharide 
and Akt-mediated activation of NF-κB [9, 10]. 
The results also showed that the number of foci of steatosis 
decreased significantly following the administration of lunasin at 
doses of 30 and 40 mg/kg. The identification of foci of steatosis is 
consistent with the report by Burlamaqui et al., who found steatosis 
in the liver of mice given 15 mg/kg AOM injected once a week [11]. 
The mechanism by which lunasin reduces the number of foci of 
steatosis is unknown, but is likely to be related to the cytoprotective 
Salinah et al. 
Int J App Pharm, Vol 11, Special Issue 6, 2019, 84-87 
 
87 
effect of lunasin resulting from a reduction in the level of free-radical 
reactive oxygen species production and an increase in the 
production of glutathione (GSH) [12]. Free radicals are one indicator 
of mitochondrial damage that can lead to steatosis [13], and GSH is a 
major antioxidant enzyme that is important in counteracting free 
radicals. However, studies conducted by Fernandez-Tome et al. 
found that the decrease in free radicals and increased GSH levels did 
not depend on the dose of lunasin [12]. There were no foci of 
dysplasia detected in any liver preparations. This is consistent with the 
results of a study by Karlsson et al. [11], which showed that 
administration of 2.5% DSS to mice altered liver function but produced 
no detectable histopathological abnormalities [14]. The present study 
used 2% DSS solution, slightly weaker than that used by Karlsson et al., 
but their results indicate that the lack of dysplasia seen in the present 
study was not because of the lack of a higher DSS dose. Another 
explanation is that the dose of AOM used in this study (10 mg/kg) was 
not high enough to cause hepatic failure, which Burlamaqui et al. 
reported generally requires 50–100 mg/kg [11]. The effect of lunasin 
on the number of foci of dysplasia in the liver of mice is unknown 
because this study did not find any in the control or treated groups. 
CONCLUSION 
Injection of 10 mg/kg AOM and 2% DSS can cause necrosis and 
steatosis but not dysplasia in mouse hepatocytes. Lunasin at doses of 
30 mg/kg and above can significantly inhibit the formation of focal 
necrosis and steatosis. 
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